AACR21 roundup: Ar­cus rolls out PhI da­ta on adeno­sine block­er for CRC; Co­di­ak's en­gi­neered ex­o­some for IL-12 shows ear­ly promise

Ar­cus Bio­sciences’ adeno­sine block­er etru­madenant showed some ben­e­fit in ex­tend­ing pa­tients’ lives as part of a Phase I/Ib tri­al in third-line-or-lat­er col­orec­tal can­cer pa­tients, ac­cord­ing to da­ta pre­sent­ed Sat­ur­day at the vir­tu­al AACR an­nu­al meet­ing.

Etru­madenant, a dual adeno­sine A2aR/A2b re­cep­tor an­tag­o­nist, is de­signed to in­hib­it adeno­sine’s role in pre­vent­ing lym­pocytes like CD8+ ef­fec­tor T cells and NK cells from in­fil­trat­ing the tu­mor mi­croen­vi­ron­ment, the com­pa­ny said. A com­bi­na­tion of etru­madenant and chemother­a­py reg­i­men FOL­FOX-6 post­ed a me­di­an PFS of 4.2 months, a me­di­an OS of 13.6 months and an ob­jec­tive re­sponse rate of 9.1%. The drug showed con­sis­tent ben­e­fits in BRAF/RAS mu­tat­ed can­cer cells, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER